What’s New in Non-Hodgkin Lymphoma Research and Treatment?

Research into the causes, prevention, and treatment of non-Hodgkin lymphoma (NHL) is being done in many medical centers throughout the world.


Scientists are making a lot of progress in understanding how changes in the DNA inside normal lymphocytes can cause them to develop into lymphoma cells. Once this is understood, drugs may be developed that block these processes. 

Progress in understanding DNA changes in lymphoma cells has already led to improved and highly sensitive tests for detecting this disease. Some of these tests are already in use, and others are being developed. They may be used to:

  • Detect lymphoma cells in a biopsy sample
  • Determine what type of lymphoma a person has
  • Help determine if a lymphoma is likely to grow and spread, even within a certain subtype of lymphoma
  • Help figure out if a certain treatment is likely to be helpful
  • Help determine if a lymphoma has been destroyed by treatment or if a relapse is likely

For example, in recent years, genetic tests have shown that there are different subtypes of diffuse large B-cell lymphoma (DLBCL), even though they look the same under the microscope. These subtypes seem to have different outcomes (prognoses) and responses to treatment. The hope is that such tests can be used to help guide treatment decisions.


Much of the research being done on NHL is focused on looking at new and better ways to treat this disease.


Many new chemotherapy drugs are being studied in clinical trials. In recent years, these studies have led to the approval of drugs such as bendamustine (Treanda) and pralatrexate (Folotyn) for use against certain types of lymphoma. Other studies are looking at new ways to combine drugs using different doses or different sequences of drugs.

Stem cell transplants

Researchers continue to improve stem cell transplant methods, including new ways to collect the stem cells before the transplant.

Autologous transplants (which use stem cells from the patient rather than from another person) have the risk of reintroducing lymphoma cells back into the patient after treatment. Researchers are testing new and improved ways to separate out the last traces of lymphoma cells from the stem cells before they are returned to the patient. Some of the new monoclonal antibodies developed for treating lymphoma may help remove these remaining cells.

Researchers are also studying the effectiveness of non-myeloablative (reduced-intensity) stem cell transplants in people with lymphoma. This approach may allow more people to benefit from stem cell transplants, especially those who are older or otherwise in poor health.

Targeted therapies

As researchers have learned more about lymphoma cells, they have developed newer drugs that target specific parts of these cells. These targeted drugs are different from standard chemotherapy drugs, which work by attacking rapidly growing cells. Targeted drugs may work in some cases where chemotherapy doesn’t, and they often have different side effects.

Some targeted drugs, such as ibrutinib (Imbruvica) and idelalisib (Zydelig), are already being used to treat some types of NHL, and are being studied for use against other types. 

Some other targeted drugs that have shown promise against lymphoma in early studies include:

  • Phosphatidyl-inositide 3 kinase (PI3K) inhibitors, such as duvelisib and copanlisib
  • BCL-2 inhibitors, such as venetoclax (Venclexta)
  • Janus kinase (JAK) inhibitors, such as ruxolitinib
  • Tyrosine kinase inhibitors, such as crizotinib, for lymphomas that express the ALK protein.

These and many other targeted drugs are now being studied in clinical trials.


Doctors have known for some time that people’s immune systems may help fight their cancer. Scientists are now trying to develop ways to encourage this immune reaction. Some types of immunotherapy are already being used to treat lymphoma, as discussed in Immunotherapy for Non-Hodgkin Lymphoma.

Monoclonal antibodies: Lymphoma cells have certain proteins on their surface. Monoclonal antibodies can be made to target these proteins and destroy the lymphoma cells while causing little damage to normal body tissues. This treatment strategy has already proven effective. Several such drugs, including rituximab (Rituxan), are already used to treat lymphoma.

Many new monoclonal antibodies are being developed as well. One example is epratuzumab, which targets the CD22 antigen on certain lymphoma cells.

Some newer antibodies are attached to substances that can poison cancer cells, and are known as antibody-drug conjugates (ADCs) or immunotoxins. They act as homing devices to deliver the toxins directly to the cancer cells. For example: 

  • Brentuximab vedotin (Adcetris) is made up of an antibody to CD30 that is attached to a cell poison. It has been shown to help treat patients with anaplastic large cell lymphoma (ALCL), and is now being studied for use against other types of lymphoma. 
  • CAT-8015 (moxetumomab pasudotox) targets the CD22 antigen on certain lymphoma cells, bringing along a toxin known as PE38. An earlier version of this drug showed a great deal of promise in treating hairy cell leukemia (HCL) in early clinical trials. 

Several other ADCs are now being studied as well, including pinatuzumab vedotin and IMG529.

Immune checkpoint inhibitors: Immune system cells normally have substances that act as checkpoints to keep them from attacking other healthy cells in the body. Cancer cells sometimes take advantage of these checkpoints to avoid being attacked by the immune system. Some newer drugs, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), work by blocking these checkpoints, which can boost the immune response against cancer cells. These drugs have shown promise in treating several types of cancer, and are now being studied for use against some types of lymphoma.

Chimeric antigen receptor (CAR) T-cell therapy: In this treatment, immune cells called T cells are removed from the patient’s blood and altered in the lab to have specific receptors (called chimeric antigen receptors, or CARs) on their surface. These receptors can attach to proteins on the surface of lymphoma cells. The T cells are then multiplied in the lab and given back into the patient’s blood, where they can seek out the lymphoma cells and launch a precise immune attack against them.

This technique has shown encouraging results in early clinical trials against some hard-to-treat lymphomas. Doctors are still improving how they make the T cells and are learning the best ways to use them. There is one FDA approved CAR T-cell therapy for certain kinds of advanced or recurrent large B-cell lymphoma.  CAR T-cell therapy for other types of non-Hodgkin lymphoma is only available in clinical trials at this time.

Lymphoma vaccines: Unlike vaccines against infections like measles or mumps, these vaccines are designed to help treat, not prevent, lymphomas. The goal is to create an immune reaction against lymphoma cells in patients who have very early disease or in patients whose disease is in remission. One possible advantage of these types of treatments is that they seem to have very limited side effects. So far, there have been a few successes with this approach, and it’s a major area of research in lymphoma treatment. At this time, lymphoma vaccines are only available in clinical trials


Some types of lymphoma are strongly linked to infections. Researchers are finding that in some cases, treating the infection actually helps treat the lymphoma. For example, gastric MALT lymphoma, which is linked to infection by the bacteria Helicobacter pylori, can often be treated with antibiotics. MALT lymphoma of the tissues around the eye (called ocular adnexal marginal zone lymphoma) has been linked to infection with the bacterium Chlamydophila psittaci. Some research has shown that treating this infection with an antibiotic (doxycycline) might make this lymphoma get better or even go away. More studies may be needed before antibiotics become part of the standard treatment for this type of lymphoma. 

The American Cancer Society medical and editorial content team
Our team is made up of doctors and master's-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: Final results of an international phase II trial. J Clin Oncol. 2012;30:2988-2994.

Freedman AS, Jacobson CA, Mauch P, Aster JC. Chapter 103: Non-Hodgkin’s lymphoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27:2983-2990.

Roschewski MJ, Wilson WH. Chapter 106: Non-Hodgkin Lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014.

Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507-516.

Last Medical Review: May 31, 2016 Last Revised: January 23, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.